SAN DIEGO, CA March 12, 2014/MarketWire– Aegis Therapeutics LLC’s Intravail® technology has been successfully formulated with phenylephrine in compressed tablets, dramatically improving oral bioavailability by more than 50%. This is the first application of Intravail® in a solid dosage form. The Intravail formulation is compatible with current tableting processes employed for OTC and prescription drugs and does not alter tablet size or appearance. Previously published studies have shown that Intravail® alkylsaccharide excipients increase oral bioavailability of a number of peptide and nonpeptide drugs in preclinical studies. Examples include exenatide, octreotide, desmopressin, heparin, sumatriptan and a 7kDa antisense (nucleotide analog) drug. In these latter applications, Intravail was incorporated into aqueous formulations or fast dissolve or chewable formats. The extension of the use of Intravail® into solid dosage forms represents a significant expansion of the broad applicability of this technology. Intravail® excipients are equally soluble in pharmaceutically accepted oils thus permitting use as oral absorption enhancers in gel caps as well.
Sixteen US and foreign patents have issued to date and Notice of Allowance has been received on two additional patents that will issue shortly covering various aspects of the Intravail®/ProTek® alkylsaccharide-based technologies. More than 50 additional patent applications are currently pending.
Aegis licenses its Intravail® drug delivery and ProTek® protein stabilization technologies to biopharmaceutical companies worldwide and is now seeking licensees for the application of Intravail to a broad range of over-the-counter drugs where increased bioavailability or more rapid onset of action would offer improved performance and significant market differentiation in a crowded field.
To receive future press releases directly via email click here and enter your email address in the sign-up box at the bottom of the page.
About Aegis Therapeutics
Aegis Therapeutics LLC commercializes its patented drug formulation technologies through product-specific licenses. Intravail® drug delivery technology enables non-invasive delivery of a broad range of protein, peptide and non-peptide drugs that can currently only be administered by injection, via the oral, buccal, and intranasal administration routes, and with high bioavailability. Our ProTek® excipients stabilize, prevent aggregation, and reduce unwanted immunogenicity of protein and peptide therapeutics while avoiding oxidative damage caused by polysorbate surfactants.
For more information about Aegis, please visit: http://www.aegisthera.com.